Literature DB >> 14680434

Current therapy of ulcerative colitis in children.

Alan Ronald Bremner1, David Mervyn Griffiths, Robert Mark Beattie.   

Abstract

Ulcerative colitis presents in childhood in 10% of those affected, usually with pancolitis. Important features in management include growth, development and avoidance of treatment toxicity. This review addresses the current treatment options including both the paediatric evidence-based experience and areas where paediatric practice is informed by adult studies. Standard treatments include sulfasalazine or 5-aminosalicylates, corticosteroids, purine derivatives (azathioprine or 6-mercaptopurine) and surgery. Other immunosuppressant therapies and the emerging roles for biological therapies and probiotics are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14680434     DOI: 10.1517/14656566.5.1.37

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  2 in total

Review 1.  Inflammatory bowel disease.

Authors:  R M Beattie; N M Croft; J M Fell; N A Afzal; R B Heuschkel
Journal:  Arch Dis Child       Date:  2006-05       Impact factor: 3.791

2.  Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study.

Authors:  J Antonio Quiros; Melvin B Heyman; John F Pohl; Thomas M Attard; Henry J Pieniaszek; Enoch Bortey; Kelli Walker; William P Forbes
Journal:  J Pediatr Gastroenterol Nutr       Date:  2009-11       Impact factor: 2.839

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.